Aubagio®: Efficacy and Safety in RRMS Management
Register for Insights on Aubagio®'s Impact on RRMS
Log in or Register now to delve into Aubagio®'s demonstrated efficacy in managing RRMS1,2. Discover its effectiveness in reducing relapse rates2,3 delaying disability progression2,3, and maintaining brain volume through clinical trials and real-world data1. Gain access to comprehensive insights.
References
- Aubagio Smpc Oct 2019.
- O’Connor P, Wolinsky JS, Confavreux C, et al; for the TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
- Confavreux C, O’Connor P, Comi G, et al; for the TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256.
- O’Connor P, Comi G, Freedman MS, et al; for the Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86(10):920-930.
- Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97-104.
To continue reading confirm that you are a healthcare professional
Click login to continue